 |
|
|---|---|
| Systematic (IUPAC) name | |
| (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 135306-39-7 |
| ATC code | None |
| PubChem | CID 60829 |
| UNII | J8IE53G2IV  |
| Chemical data | |
| Formula | C12H15F2NO2 |
| Mol. mass | 243.249 g/mol |
|
|
 (what is this?) (verify) |
|
Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, the active metabolite of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications,[1][2] but no results have been reported following these initial trials and its current status is unclear.
See also [edit]
References [edit]
- ^ DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, Laurenza A, Barrows CE, Webster CJ, Stotka CJ, Asgharnejad M. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry. 2002 Aug;41(8):914-20. PMID 12162627
- ^ Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, Stubbins M, Roses AD. Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenetics and Genomics. 2005 Dec;15(12):883-9. PMID 16272960
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Original courtesy of Wikipedia: http://en.wikipedia.org/wiki/Manifaxine — Please support Wikipedia.
A portion of the proceeds from advertising on Digplanet goes to supporting Wikipedia.
A portion of the proceeds from advertising on Digplanet goes to supporting Wikipedia.
